The new system was designed, tested and approved for use with magnetic resonance imaging (MRI) under specified scanning conditions, and is now commercially available in select European countries.
Patients receiving the EnRhythm MRI SureScan pacing system will be able to undergo MRI scans under certain conditions, representing a major milestone in the evolution of implantable cardiac devices, the company said.
Alain Coudray, vice president of cardiac rhythm disease management business for western Europe at Medtronic, said: “Medtronic recognizes the complex needs of today’s patient and will continue to develop advancements in pacemaker technology and other devices that allow patients to receive optimal medical care.”